Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-AD adjuvant dabrafenib + trametinib in resected BRAF V600-mutant stage III melanoma
NL-OMON56172Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) comparing Dabrafenib + trametinib with Placebo + placebo (2 arms). Primary endpoint: Relapse-free survival. Started Nov 2013; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON56172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56172.